Food Does Not Influence the Pharmacokinetics of a New Extended Release Formulation of Tolterodine for Once Daily Treatment of Patients with Overactive Bladder

By Olsson B.  

Clinical Pharmacokinetics, Vol. 40, Iss. 2, 2001-01 ,pp. : 135-143

Adis International

Access to resources Recommend Favorite

Oxybutynin Extended Release and Tolterodine Immediate Release: A Health Economic Comparison

By Getsios D.  

Clinical Drug Investigation, Vol. 24, Iss. 2, 2004-01 ,pp. : 81-88

Adis International

Access to resources Recommend Favorite

Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

By Gayatri Sathyan  

Clinical Pharmacokinetics, Vol. 43, Iss. 14, 2004-01 ,pp. : 1059-1068

Adis International

Access to resources Recommend Favorite

Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release 30 mg versus Cyclobenzaprine Immediate Release 10 mg Three Times Daily in Healthy Young Adults: A Randomized, Open-Label, Two-Period Crossover, Single-Centre Study

By Darwish Mona   Hellriegel Edward T.   Xie Fang  

Clinical Drug Investigation, Vol. 28, Iss. 12, 2008-01 ,pp. : 793-801

Adis International

Access to resources Recommend Favorite

Comparison of the Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg and Cyclobenzaprine Immediate-Release 10 mg Three Times Daily in the Elderly: A Randomized, Open-Label, Crossover Study

By Darwish Mona  

Drugs & Aging, Vol. 26, Iss. 2, 2009-01 ,pp. : 95-101

Adis International

Access to resources Recommend Favorite